Bruno R Tegel1,2, Steffen Huber1, Lynn J Savic1,2, MingDe Lin3, Bernhard Gebauer2, Jeffrey Pollak1, Julius Chapiro1. 1. Yale School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT, USA. 2. Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität Berlin and Berlin Institute of Health, Institute of Radiology, Berlin, Germany. 3. U/S Imaging and Interventions, Philips Research North America, Cambridge, MA, USA.
Abstract
BACKGROUND: The prognosis of patients with renal cell carcinoma (RCC) depends greatly on the presence of extra-renal metastases. PURPOSE: To investigate the value of total tumor volume (TTV) and enhancing tumor volume (ETV) as three-dimensional (3D) quantitative imaging biomarkers for disease aggressiveness in patients with RCC. MATERIAL AND METHODS: Retrospective, HIPAA-compliant, IRB-approved study including 37 patients with RCC treated with image-guided thermal ablation during 2007-2015. TNM stage, RENAL Nephrometry Score, largest tumor diameter, TTV, and ETV were assessed on cross-sectional imaging at baseline and correlated with outcome measurements. The primary outcome was time-to-occurrence of extra-renal metastases and the secondary outcome was progression-free survival (PFS). Correlation was assessed using a Cox regression model and differences in outcomes were shown by Kaplan-Meier plots with significance and odds ratios (OR) calculated by Log-rank test/generalized Wilcoxon and continuity-corrected Woolf logit method. RESULTS: Patients with a TTV or ETV > 5 cm3 were more likely to develop distant metastases compared to patients with TTV (OR 6.69, 95% confidence interval [CI] 0.33-134.4, P=0.022) or ETV (OR 8.48, 95% CI 0.42-170.1, P=0.016) < 5 cm3. Additionally, PFS was significantly worse in patients with larger ETV (P = 0.039; median PFS 51.87 months vs. 69.97 months). In contrast, stratification by median value of the established, caliper-based measurements showed no significant correlation with outcome parameters. CONCLUSION: ETV, as surrogate of lesion vascularity, is a sensitive imaging biomarker for occurrence of extra-renal metastatic disease and PFS in patients with RCC.
BACKGROUND: The prognosis of patients with renal cell carcinoma (RCC) depends greatly on the presence of extra-renal metastases. PURPOSE: To investigate the value of total tumor volume (TTV) and enhancing tumor volume (ETV) as three-dimensional (3D) quantitative imaging biomarkers for disease aggressiveness in patients with RCC. MATERIAL AND METHODS: Retrospective, HIPAA-compliant, IRB-approved study including 37 patients with RCC treated with image-guided thermal ablation during 2007-2015. TNM stage, RENAL Nephrometry Score, largest tumor diameter, TTV, and ETV were assessed on cross-sectional imaging at baseline and correlated with outcome measurements. The primary outcome was time-to-occurrence of extra-renal metastases and the secondary outcome was progression-free survival (PFS). Correlation was assessed using a Cox regression model and differences in outcomes were shown by Kaplan-Meier plots with significance and odds ratios (OR) calculated by Log-rank test/generalized Wilcoxon and continuity-corrected Woolf logit method. RESULTS:Patients with a TTV or ETV > 5 cm3 were more likely to develop distant metastases compared to patients with TTV (OR 6.69, 95% confidence interval [CI] 0.33-134.4, P=0.022) or ETV (OR 8.48, 95% CI 0.42-170.1, P=0.016) < 5 cm3. Additionally, PFS was significantly worse in patients with larger ETV (P = 0.039; median PFS 51.87 months vs. 69.97 months). In contrast, stratification by median value of the established, caliper-based measurements showed no significant correlation with outcome parameters. CONCLUSION:ETV, as surrogate of lesion vascularity, is a sensitive imaging biomarker for occurrence of extra-renal metastatic disease and PFS in patients with RCC.
Authors: Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo Journal: J Urol Date: 2009-08-14 Impact factor: 7.450
Authors: Ganesh V Raj; R Houston Thompson; Bradley C Leibovich; Michael L Blute; Paul Russo; Michael W Kattan Journal: J Urol Date: 2008-04-18 Impact factor: 7.450
Authors: James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra Journal: Nat Rev Dis Primers Date: 2017-03-09 Impact factor: 52.329
Authors: Martin Pichler; Georg C Hutterer; Thomas F Chromecki; Johanna Jesche; Karin Kampel-Kettner; Andrea Groselj-Strele; Gerald Hoefler; Karl Pummer; Richard Zigeuner Journal: Histopathology Date: 2012-09-28 Impact factor: 5.087
Authors: Heidi Coy; Jonathan R Young; Michael L Douek; Alan Pantuck; Matthew S Brown; James Sayre; Steven S Raman Journal: Abdom Radiol (NY) Date: 2019-01
Authors: Brett Delahunt; Lars Egevad; Hemamali Samaratunga; Guido Martignoni; John N Nacey; John R Srigley Journal: Histopathology Date: 2015-11-16 Impact factor: 5.087
Authors: Qingbo Yin; Sheng-Che Hung; Li Wang; Weili Lin; Julia R Fielding; W Kimryn Rathmell; Amir H Khandani; Michael E Woods; Matthew I Milowsky; Samira A Brooks; Eric M Wallen; Dinggang Shen Journal: Sci Rep Date: 2017-03-03 Impact factor: 4.379